Related Experiment Video

Updated: Jul 16, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

483

Critical requirement of SOS1 for tumor development and microenvironment modulation in KRASG12D-driven lung

Fernando C Baltanás1,2, Rósula García-Navas3, Pablo Rodríguez-Ramos3

  • 1Lab 1. Cancer Research Center, Institute of Cancer Molecular and Cellular Biology, CSIC-University of Salamanca and CIBERONC, 37007, Salamanca, Spain. fcalvo@us.es.

Nature Communications
|September 20, 2023
PubMed

Insights

Targeting SOS1 significantly improves survival in KRASG12D-driven lung adenocarcinoma (LUAD) by reducing tumor burden and altering the tumor microenvironment (TME). This highlights SOS1 as a key therapeutic target for LUAD.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • KRAS mutations are common drivers of lung adenocarcinoma (LUAD).
  • SOS proteins (SOS1 and SOS2) are guanine nucleotide exchange factors (GEFs) for RAS proteins.
  • Targeting KRAS-driven pathways is crucial for LUAD treatment.

Purpose of the Study:

  • To investigate the impact of genetic ablation of SOS1 and SOS2 on KRASG12D-driven LUAD.
  • To evaluate SOS1 as a potential therapeutic target in LUAD.

Main Methods:

  • Murine model of KRASG12D-driven lung adenocarcinoma.
  • Genetic ablation of SOS1 or SOS2.
  • Analysis of tumor burden, tumor microenvironment (TME) components (fibroblasts, macrophages, T-lymphocytes).
  • In vivo tumor cell injection experiments.
  • In silico analysis of human LUAD databases.

Main Results:

  • SOS2 ablation offered limited early-stage protection.
  • SOS1 ablation significantly increased survival and lifespan in KRASG12D mice.
  • SOS1 ablation reduced tumor burden and altered TME composition.
  • SOS1 ablation induced shrinkage and regression of established LUAD tumors.
  • In silico data supported SOS1's role in LUAD patient survival.

Conclusions:

  • SOS1 is critically required for the development of KRASG12D-driven LUAD.
  • SOS1 ablation demonstrates significant therapeutic potential in LUAD.
  • SOS1 is a validated actionable therapeutic target for KRAS mutant LUAD.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K
The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues07:39

The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues

Published on: June 16, 2018

9.3K

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.0K